在COVID-19高血压患者中使用性类固醇:一项探索性研究
Pavitra Kotini-Shah1, Shaveta Khosla1, Felipe Borges Almeida2,3
1Department of Emergency Medicine, College of Medicine, University of Illinois Chicago, 808 S. Wood St., MC 724, Chicago, IL 60612, USA.
International journal of molecular sciences
|September 27, 2025
概括
COVID-19的结果显示了性别差异. 这项研究在高血压的COVID-19患者中发现了独特的性激素配置,其水平根据疾病严重程度而变化,并表明了潜在的治疗点.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 传染性疾病 传染性疾病
背景情况:
- 性别和性别差异显著影响COVID-19的结果,男性住院和死亡率更高.
- 性激素 (雌激素,孕,) 涉及炎症,免疫反应和血管健康,但它们在COVID-19严重性,特别是高血压方面的作用尚不清楚.
研究的目的:
- 在高血压的COVID-19患者中调查循环性激素水平和神经活性代谢物.
- 为了确定这些荷尔蒙特征与COVID-19疾病严重程度之间的关联.
主要方法:
- 测量血清性激素 (雌激素,孕,) 和神经活性代谢物.
- 对116名高血压COVID-19患者的激素水平的分析,按性别,更年期状态和疾病严重程度 (住院治疗,ICU入院) 分层.
主要成果:
- 观察到不同的基于性别的荷尔蒙特征. 男性的雌激素和丸激素水平较高;绝经后的女性的孕激素水平较高.
- 住院患者的雌激素和孕激素水平升高,而ICU患者的三种激素水平较低.
- 发现了特定的代谢物相关性:男性的3α-diol升高与住院/ICU相关;较低的allopregnanolone和estradiol与缺氧相关.
结论:
- 在高血压患者中,对COVID-19的进展发生了一个动态的,性别特定的荷尔蒙反应.
- 保护性类固醇的早期增加和晚期减少表明存在复杂的调节机制.
- 这些发现可能有助于临床风险分层和针对性别的COVID-19疗法.
相关概念视频
Hypertension III: Clinical Manifestations and Diagnostic Studies
471
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
471
Hypertension II: Pathophysiology
795
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
795
Hypertension I: Introduction
743
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
743
Hypertension IV: Drug Therapy and Lifestyle Modifications
624
Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
624
Hypertension and Regulation of Blood Pressure
3.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
3.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
441
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
441

